GeneDx reported preliminary financial results for the fourth quarter and full year of 2025, showcasing significant revenue growth.
The full year 2025 revenues are expected to reach $427 million, driven by a notable increase in exome and genome revenue.
Looking ahead to 2026, GeneDx anticipates revenues ranging between $540 and $555 million, with a continued emphasis on exome and genome volume expansion.
Revenue Growth
GeneDx expects a substantial 41% year-over-year increase in revenues for the full year 2025, reflecting strong performance.
Exome and Genome Revenue Increase
The company projects a remarkable 54% growth in exome and genome revenue for 2025 compared to the previous year, indicating accelerating demand for genetic testing services.
Volume Growth
Throughout 2025, GeneDx witnessed consistent growth in exome and genome test volumes, with a notable surge in the fourth quarter, highlighting rising adoption rates for its services.
Gross Margin
For the full year 2025, GeneDx is targeting a robust GAAP and adjusted gross margin of 71%, indicating efficient cost management and pricing strategies.
2026 Guidance
Management is optimistic about 2026, projecting a 33-35% growth in exome and genome revenue, signaling confidence in sustained demand and market positioning.
- GeneDx's robust revenue growth in 2025 underscores the efficacy of its genomic insights strategy, demonstrating the company's ability to capture market share and deliver value-added genomic services.
- The strategic focus on accelerating diagnoses through technological investments positions GeneDx for continued growth by addressing customer needs and enhancing operational efficiencies.
GeneDx's consistent revenue growth, innovative approach to genetic diagnostics, and commitment to scalable profitability establish a strong foundation for its leadership in the dynamic genomics sector, signaling promising prospects for future growth and shareholder value creation.